|

Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma

RECRUITINGEarly 1Sponsored by Xinxin Zhang
Actively Recruiting
PhaseEarly 1
SponsorXinxin Zhang
Started2025-10-13
Est. completion2027-05-01
Eligibility
Age6 Years+
Healthy vol.Accepted

Summary

An Exploratory Study on the Use of mRNA Tumor Vaccines in the Treatment of Refractory Rhabdomyosarcoma

Eligibility

Age: 6 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Diagnosed with rhabdomyosarcoma confirmed by pathological or molecular testing;
2. Age ≥ 6 years;
3. Has residual tumor or minor disease progression following standard therapy, and has no available effective treatment option. (\*: Prior to vaccine administration, during the vaccine manufacturing period, continuation of the prior antitumor regimen is permitted in combination with the study drug(s).)
4. Expected survival time greater than 6 months;
5. ECOG performance status score of 0-1; -

Exclusion Criteria:

* 1.History of or concurrent with other untreated malignant tumors, except for previously cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and superficial bladder cancer; 2.History of or current active autoimmune diseases. 3.Has uncontrolled cardiovascular diseases.

Conditions2

CancerRhabdomyosarcoma

Interventions1

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.